180 related articles for article (PubMed ID: 37042949)
1. Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells.
Chang YT; Chiu I; Wang Q; Bustamante J; Jiang W; Rycaj K; Yi S; Li J; Kowalski-Muegge J; Matsui W
Blood Adv; 2023 Jul; 7(14):3551-3560. PubMed ID: 37042949
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.
Nefedova Y; Sullivan DM; Bolick SC; Dalton WS; Gabrilovich DI
Blood; 2008 Feb; 111(4):2220-9. PubMed ID: 18039953
[TBL] [Abstract][Full Text] [Related]
3. RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.
Surget S; Descamps G; Brosseau C; Normant V; Maïga S; Gomez-Bougie P; Gouy-Colin N; Godon C; Béné MC; Moreau P; Le Gouill S; Amiot M; Pellat-Deceunynck C
BMC Cancer; 2014 Jun; 14():437. PubMed ID: 24927749
[TBL] [Abstract][Full Text] [Related]
4. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
5. Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.
Singh RK; Jones RJ; Shirazi F; Qin L; Zou J; Hong S; Wang H; Lee HC; Patel KK; Wan J; Choudhary RK; Kuiatse I; Pahl A; Orlowski RZ
Res Sq; 2024 Jan; ():. PubMed ID: 38260385
[TBL] [Abstract][Full Text] [Related]
6. Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
Munawar U; Roth M; Barrio S; Wajant H; Siegmund D; Bargou RC; Kortüm KM; Stühmer T
Sci Rep; 2019 Dec; 9(1):18062. PubMed ID: 31792264
[TBL] [Abstract][Full Text] [Related]
7. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Chen MH; Qi CX; Saha MN; Chang H
Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
[TBL] [Abstract][Full Text] [Related]
8. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity.
Sabol HM; Ferrari AJ; Adhikari M; Amorim T; McAndrews K; Anderson J; Vigolo M; Lehal R; Cregor M; Khan S; Cuevas PL; Helms JA; Kurihara N; Srinivasan V; Ebetino FH; Boeckman RK; Roodman GD; Bellido T; Delgado-Calle J
Cancer Res; 2021 Oct; 81(19):5102-5114. PubMed ID: 34348968
[TBL] [Abstract][Full Text] [Related]
9. MAML1 regulates cell viability via the NF-κB pathway in cervical cancer cell lines.
Kuncharin Y; Sangphech N; Kueanjinda P; Bhattarakosol P; Palaga T
Exp Cell Res; 2011 Aug; 317(13):1830-40. PubMed ID: 21640102
[TBL] [Abstract][Full Text] [Related]
10. Antisense p53 transduction leads to overexpression of bcl-2 and dexamethasone resistance in multiple myeloma.
Iyer R; Ding L; Batchu RB; Naugler S; Shammas MA; Munshi NC
Leuk Res; 2003 Jan; 27(1):73-8. PubMed ID: 12479855
[TBL] [Abstract][Full Text] [Related]
11. NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.
Huang J; Zhou Y; Thomas GS; Gu Z; Yang Y; Xu H; Tricot G; Zhan F
Clin Cancer Res; 2015 Dec; 21(24):5532-42. PubMed ID: 26156395
[TBL] [Abstract][Full Text] [Related]
12. Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties.
Aoki S; Mizuma M; Takahashi Y; Haji Y; Okada R; Abe T; Karasawa H; Tamai K; Okada T; Morikawa T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Katayose Y; Unno M
BMC Cancer; 2016 Nov; 16(1):854. PubMed ID: 27821106
[TBL] [Abstract][Full Text] [Related]
13. p53 haploinsufficiency and functional abnormalities in multiple myeloma.
Teoh PJ; Chung TH; Sebastian S; Choo SN; Yan J; Ng SB; Fonseca R; Chng WJ
Leukemia; 2014 Oct; 28(10):2066-74. PubMed ID: 24625551
[TBL] [Abstract][Full Text] [Related]
14. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
Zhao JJ; Chu ZB; Hu Y; Lin J; Wang Z; Jiang M; Chen M; Wang X; Kang Y; Zhou Y; Ni Chonghaile T; Johncilla ME; Tai YT; Cheng JQ; Letai A; Munshi NC; Anderson KC; Carrasco RD
Cancer Res; 2015 Oct; 75(20):4384-4397. PubMed ID: 26249174
[TBL] [Abstract][Full Text] [Related]
15. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
16. Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Kortüm KM; Langer C; Monge J; Bruins L; Egan JB; Zhu YX; Shi CX; Jedlowski P; Schmidt J; Ojha J; Bullinger L; Liebisch P; Kull M; Champion MD; Van Wier S; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Br J Haematol; 2015 Feb; 168(4):507-10. PubMed ID: 25302557
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
18. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells.
Anthoney DA; McIlwrath AJ; Gallagher WM; Edlin AR; Brown R
Cancer Res; 1996 Mar; 56(6):1374-81. PubMed ID: 8640828
[TBL] [Abstract][Full Text] [Related]
19. PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance.
Tessoulin B; Descamps G; Moreau P; Maïga S; Lodé L; Godon C; Marionneau-Lambot S; Oullier T; Le Gouill S; Amiot M; Pellat-Deceunynck C
Blood; 2014 Sep; 124(10):1626-36. PubMed ID: 25006124
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
